主权项 |
1. A method of treating a human patient for Alzheimer's disease, comprising: administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor selected from: NGF, BDNF, NT-3, NT-4/5, NT-6, GDNF, CNTF, LIF, IGF-1, b-FGF, neurturin, persephin, artemin, TGFα, TGFβ, IGF-2, PDGF, EGF, cardiotropin, IGF, VEGF, Sonic hedgehog (SHH), BMP, FGF20, VIP, pleiotrophin (PTN), and HGF; wherein said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor, wherein there is cessation of growth factor delivery during the intermissions between administrations, wherein the intermissions between administration of said growth factor are at least about one week, wherein said Alzheimer's disease is treated. |